Physician profile
Uzma Zafar
NPI 1770556185
$3,947.87
in general payments reported to CMS, 2019-2025
28 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $394 · 2021: $319 · 2022: $296 · 2023: $346 · 2024: $836 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $784.13 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $646.84 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $623.71 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $427.65 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $215.44 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $181.26 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $160.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $150.19 | 2019-2024 | Spravato |
| Neurocrine Biosciences, INC. | $113.49 | 2019-2025 | Ingrezza |
| Brainsway USA INC | $81.88 | 2019 | |
| Vanda Pharmaceuticals INC. | $75.52 | 2019-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $66.82 | 2023 | Quviviq |
| Corium, LLC | $56.63 | 2024 | Azstarys |
| Bausch Health US, LLC | $45.66 | 2022-2024 | Aplenzin |
| Allergan, INC. | $32.78 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.48 | 2024 | Cobenfy |
| Shire North American Group INC | $32.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $27.58 | 2024-2025 | Qelbree |
| Alkermes, INC. | $27.06 | 2024 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $24.83 | 2019 | |
| Acadia Pharmaceuticals INC | $23.96 | 2020 | |
| Bioxcel Therapeutics, INC. | $22.17 | 2023 | Igalmi |
| Indivior INC. | $21.80 | 2024 | Perseris |
| Merck Sharp & Dohme LLC | $18.66 | 2019 | |
| Almatica Pharma LLC | $17.18 | 2024 | Loreev Xr |
| Sage Therapeutics, LLC | $14.33 | 2024 | |
| Lilly USA, LLC | $13.14 | 2022 | |
| Neuronetics, INC. | $10.33 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.